Publikasi Scopus Covid-19 Per 15 Juni 2023 (346 artikel)

Rajabto, Wulyo (36519576100); Chandika, Vitya (57742604100); Harahap, Agnes Stephanie (57218511857); Ham, Maria Francisca (7004830001)
Rajabto W.; Chandika V.; Harahap A.S.; Ham M.F.
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
International Medical Case Reports Journal
Background: Salvage conventional chemotherapy followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is the treatment of choice for most patients with refractory classical Hodgkin lymphoma (cHL). In the era of pandemic COVID-1
brentuximab vedotin; COVID-19; monotherapy; refractory Hodgkin’s lymphoma
V. Chandika; Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Central Jakarta, Jalan Pangeran Diponegoro No. 71, 10430, Indonesia; email: vityacha
Dove Medical Press Ltd
1179142X
Int. Med. Case Rep. J.
Rajabto W., Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jalan Pangeran Diponegoro No. 71, Central Jakarta, 10430, Indonesia, Department of In
Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jalan Pangeran Diponegoro No. 71, Central Jakarta, 10430, Indonesia; Department of Internal Medic
36519576100; 57742604100; 57218511857; 7004830001
0
2022
Article